Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Jean-Dominique Pierret

Jean-Dominique Pierret

Customer Consultant, Pharmacovigilance & Safety at Elsevier

Connect with Jean-Dominique Pierret on LinkedIn

About the author: Dealing with information overload, finding the right article to stimulate creativity or thinking, accessing the data required to make a less risky decision, connecting disjointed information to generate hypotheses … these are some of the topics that are of great interest to Jean-Dominique. In this blog, he would like to share with you thoughts and ideas around those subjects, with a focus on information for drug safety and pharmacovigilance. Jean-Dominique spent 20+ years in the pharmaceutical industry as a scientific information expert, supporting teams from drug discovery to medical affairs, including pharmacovigilance and drug development.

Posts by Jean-Dominique Pierret

Dedication to science drives a 20-year relationship between an information expert and a distinguished researcher

Posted on February 20th, 2020 in Pharma R&D

With about 600 articles published in major dermatology journals, almost 40 books authored, 70 chapters in various books, and a h-index of 49, Dr. Robert Baran is one of the most knowledgeable dermatologists in the world. He began publishing more than 67 years ago, is invited to many international conferences every year, and his specialty is nails.

(more…)

Why literature is a valuable source for signal detection: From the EU point of view

Posted on January 9th, 2020 in Pharmacovigilance

Signal detection is traditionally based on case reporting from healthcare professionals and national regulatory authorities. Yet, there are a number of very notable examples where a safety signal actually came from the scientific literature, such as in the cases of thalidomide, GM-CSF, nifedipine and tamsulosin. (You can learn more about how safety signals detected from a literature report had an impact on the lifecycle of these drugs here.)

(more…)